Zanubrutinib monotherapy for patients with treatment-naïve chronic lymphocytic leukemia and 17p deletion

Patients with chronic lymphocytic leukemia or small lymphocytic lymphoma whose tumors carry deletion of chromosome 17p13.1 [del(17p)] have an unfavorable prognosis and respond poorly to standard chemoimmunotherapy. Zanubrutinib is a selective next-generation Bruton tyrosine kinase inhibitor. We eval...

Descripción completa

Detalles Bibliográficos
Autores principales: Tam, Constantine S., Robak, Tadeusz, Ghia, Paolo, Kahl, Brad S., Walker, Patricia, Janowski, Wojciech, Simpson, David, Shadman, Mazyar, Ganly, Peter S., Laurenti, Luca, Opat, Stephen, Tani, Monica, Ciepluch, Hanna, Verner, Emma, Šimkovič, Martin, Österborg, Anders, Trněný, Marek, Tedeschi, Alessandra, Paik, Jason C., Kuwahara, Sowmya B., Feng, Shibao, Ramakrishnan, Vanitha, Cohen, Aileen, Huang, Jane, Hillmen, Peter, Brown, Jennifer R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8409041/
https://www.ncbi.nlm.nih.gov/pubmed/33054121
http://dx.doi.org/10.3324/haematol.2020.259432

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8409041/
https://www.ncbi.nlm.nih.gov/pubmed/33054121
http://dx.doi.org/10.3324/haematol.2020.259432

Ejemplares similares